This study is being carried out to see if constant 3 days infusion of Nexium is effective in preventing rebleeding after an endoscopic treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
1,312
Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo
Time frame: Within 72 hours
Clinically Significant Rebleeding Within 7 Days
Time frame: Within 7 days
Clinically Significant Rebleeding Within 30 Days
Time frame: Within 30 days
Death Within 72 Hours
Time frame: Within 72 hours
Death Within 30 Days
Time frame: Within 30 days
Death Related to Rebleeding Within 30 Days as Judged by the EpC
Time frame: Within 30 days
Requirement for Surgery Within 72 Hours
Time frame: Within 72 hours
Requirement for Surgery Within 30 Days
Time frame: Within 30 days
Requirement for Endoscopic Re-treatment Within 72 Hours
Time frame: Within 72 hours
Requirement for Endoscopic Re-treatment Within 30 Days
Time frame: Within 30 days
Number of Blood Units Transfused Within 72 Hours
Time frame: Within 72 hours
Number of Blood Units Transfused Within 30 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Braunau/Inn, Austria
Research Site
Feldbach, Austria
Research Site
Graz, Austria
Research Site
Krems, Austria
Research Site
Vienna, Austria
Research Site
Wels, Austria
Research Site
Aalborg, Denmark
Research Site
Amager, Denmark
Research Site
Copenhagen, Denmark
Research Site
Glostrup Municipality, Denmark
...and 68 more locations
Time frame: within 30 days
Number of Days Hospitalized Due to Rebleeding During the 30-day Treatment Period
Time frame: Within 30 days